

What if we had built a prediction model with a survival super learner instead of a Cox model 10 years ago?

Arthur Chatton,^{1*} Émilie Pilote,¹ Kevin Assob Feugo,¹ Héloïse Cardinal,^{2,3,4} Robert W. Platt,^{5,6,7} and Mireille E. Schnitzer^{1,2,5}

¹ Faculté de Pharmacie, Université de Montréal, Montréal, QC, Canada

² Département de Médecine Sociale et Préventive, École de Santé Publique de l'Université de Montréal, Université de Montréal, Montréal, QC, Canada

³ Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, QC, Canada

⁴ Centre de recherche du Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada

⁵ Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, QC, Canada

⁶ Department of Pediatrics, McGill University, Montréal, QC, Canada

⁷ Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montréal, QC, Canada

* Corresponding author: Arthur Chatton, email: arthur.chatton@umontreal.ca

Abstract

Objective: This study sought to compare the drop in predictive performance over time according to the modeling approach (regression versus machine learning) used to build a kidney transplant failure prediction model with a time-to-event outcome.

Study Design and Setting: The *Kidney Transplant Failure Score* (KTFS) was used as a benchmark. We reused the data from which it was developed (DIVAT cohort, n=2,169) to build another prediction algorithm using a survival super learner combining (semi-)parametric and non-parametric methods. Performance in DIVAT was estimated for the two prediction models using internal validation. Then, the drop in predictive performance was evaluated in the same geographical population approximately ten years later (EKiTE cohort, n=2,329).

Results: In DIVAT, the super learner achieved better discrimination than the KTFS, with a tAUROC of 0.83 (0.79-0.87) compared to 0.76 (0.70-0.82). While the discrimination remained stable for the KTFS, it was not the case for the super learner, with a drop to 0.80 (0.76-0.83). Regarding calibration, the survival SL overestimated graft survival at development, while the KTFS underestimated graft survival ten years later. Brier score values were similar regardless of the approach and the timing.

Conclusion: The more flexible SL provided superior discrimination on the population used to fit it compared to a Cox model and similar discrimination when applied to a future dataset of the same population. Both methods are subject to calibration drift over time. However, weak calibration on the population used to develop the prediction model was correct only for the Cox model, and recalibration should be considered in the future to correct the calibration drift.

Keywords: Clinical prediction model, Kidney transplantation, Machine learning, Super learning, Survival analysis, Temporal validation.

Highlights:

- Predictive performance dropped over time for both regression-based and machine-learning-based prediction models.
- The survival super learner achieved better discrimination at the cost of a poorer weak calibration than the Cox model on development data.
- Training the survival super learner with a loss function maximizing discrimination yielded the strongest miscalibration.
- More frequent recalibrations of the score are needed when using the survival super learner.

Introduction

The need for kidney replacement therapies is a major public health issue, with worldwide use expected to total 5,439 million patients (3,899 to 7,640 million) in 2030.¹ Kidney transplantation is considered the treatment of choice, improving both quality of life and life expectancy as compared to remaining on dialysis.^{2,3} Still, there is a shortage of organs available for donation. Optimizing long-term post-transplantation care is crucial to limit the need for novel transplantations. Clinical prediction models (CPMs), or prognostic scores, can provide meaningful information for nephrologists and may help involve patients in managing their disease. When it comes to kidney transplantation, researchers often want to predict time-to-event outcomes like the return to dialysis (i.e., graft loss). For instance, Foucher et al. developed the Kidney Transplant Failure Score (KTFS) to predict the risk of graft failure seven years after the first anniversary of the transplantation,⁴ which was recently externally validated.⁵ Foucher et al. used a Cox model to build the KTFS, but alternative statistical methods can be used instead, such as accelerated failure time models,⁶ random survival forests,⁷ or deep learning.⁸ All these methods will yield a different CPM, and researchers do not know *a priori* which one is the best for their application. The super learner (SL) is an averaging method combining predictions from various statistical methods (hereafter candidate learners) into one weighted prediction. It has been shown that the resulting prediction is asymptotically at least as accurate as the best candidate learners,⁹ and was successfully applied in other domains.^{10,11} However, it has seldom been used for time-to-event outcomes,^{12,13} although it can handle such outcomes with right-censoring.^{14,15}

Unfortunately, CPM performance comparisons focus almost solely on validity at the time of development.^{12,16} However, populations naturally shift over time with, for instance, practice changes, such as the use of kidneys from donors who have risk features for suboptimal graft longevity.¹⁷ Davis et al. studied the performance evolution of CPMs over time according to the statistical method of development for binary outcomes.¹⁸ They showed that random forest and neural networks outperformed logistic regression (with or without penalization) in terms of calibration over time, while the discrimination remained similar. However, the censoring inherent to time-to-event outcomes may differentially impact the performance evolutions of regression and machine learning methods.

In this study, we sought to compare the evolution of the performance of a Cox-based CPM (the KTFS) to a survival SL-based CPM that includes random survival forests and survival neural networks. Both CPMs are built with the same data and validated temporarily on a similar population ten years later.

Material and methods

Cox-based and survival SL-based CPMs

The KTFS was developed on the French multicentric cohort DIVAT with 2169 patients included from 1997 to 2006 using a cause-specific proportional hazards Cox model.⁴ The authors stated that yearly audits between centers reported less than 1% error in the

collected data, minimizing the risk of measurement error. The study population was defined as adult recipients of neurologically deceased donors with a functional transplant on the first anniversary of their transplantation without missing predictors. The outcome was the time-to-return to dialysis over the following seven years, with censoring due to patient mortality. It includes as pre-transplant predictors recipient biological sex, recipient age, last donor creatininemia, and the number of previous transplantations; and four post-transplant predictors: creatininemia at 3 and 12 months, proteinuria at 12 months and acute rejection episode during the first year of transplantation. Note that this CPM is aimed to be used at the transplantation's first anniversary, explaining the post-transplant predictors. Non-linear functional forms or categorizations are used for continuous predictors, and interactions are also included.

We reused data from the same 2,169 individuals to build the survival SL-based CPM mimicking the KTFS. It included five regression methods – a Gamma-distributed AFT model, a Weibull-distributed AFT model, a Cox model with main terms only, an elasticnet Cox model,¹⁹ and a Royston and Parmar flexible parametric proportional-hazards model²⁰ – in addition to the random survival forest and the survival neural network.^{7,8} Therefore, the SL is based on methods varying in their model and distributional assumptions, and ways to incorporate continuous predictors and interactions, as recommended by Phillips et al.²¹ The predictions from each method were weighted and combined with the objective of minimizing the Brier Score loss function at 7 years using a 10-fold cross-validation scheme. Hyperparameters were estimated using 10-fold cross-validation nested in each previous fold. The R package survivalSL was used to carry out the described procedures.²² Package versions and values of the hyperparameters and seeds are provided in Supplementary Table 1.

Performance evaluation of the CPMs

The performances of the two CPMs were evaluated in DIVAT using bootstrap (2000 replications) for internal validation. Then, they were evaluated using the more recent French EKITE data (transplantation between 2010 and 2015).²³ EKITE is a European network that includes patients from France, Spain, Belgium, and Norway. We restricted our analysis to French patients to focus on the temporal evolution of performance without geographical disparity. We reused the eligibility criteria defined in the previous subsection and performed a complete case analysis. Therefore, we included 2329 individuals (Figure 1).




Figure 1: Flowchart for the EKITE network data analysis sample.

The discrimination was evaluated by the area under the time-dependent receiver operating curve (tAUROC) at 7 years.²⁴ The calibration was evaluated at three different levels (mean calibration, weak calibration, and moderate calibration) as recommended by Van Calster et al.²⁵, and flexible calibration curves were fitted using restricted cubic splines with five knots. Overall performance was evaluated by the Brier Score. Right-censoring was considered random/uninformative, and inverse probability weighting was used to create a hypothetical population that would have been observed had no censoring occurred.²⁶ See McLernon et al. for more information on these metrics in survival settings.²⁷ Non-parametric bootstrap (2000 iterations) was used to compute 95% CIs.

Sensitivity analyses

We performed two sensitivity analyses. First, we allowed the survival SL to select the predictors using elasticnet¹⁹ (which was removed from the pool of candidate learners) from the larger pool of predictors in DIVAT instead of using only the ones present in the KTFS. Second, we investigated two other loss functions in the survival SL instead of the Brier score: the AUROCt and the negative binomial log-likelihood.

Results

Patients characteristics

In DIVAT, the median follow-up time was 4.48 years, 182 (8.39%) patients returned to dialysis, and 1987 (91.61%) were right-censored. In EKITE, the median follow-up time was 6.07 years, 242 (10.39%) patients returned to dialysis, and 2087 (89.61%) were right-censored. Survival was similar across the temporalities (Figure 2). As expected, patient characteristics differed between the two study cohorts (Table 1). For instance, more recent donors were older, with a mean age of 55.0 years (± 16.5) compared to 45.2 years (± 15.8). The frequency of acute rejection episodes was lower for the more recent cohort of recipients (9.4% vs 23.9%).

Survival SL-based CPM

The survival SL selected only two candidate learners, the Cox model and the RSF, with respective weights of 0.857 and 0.143. Therefore, the SL's predictions were the inverse-logit of the weighted sum of the predictions from the Cox and random survival forest models. Weights were similar when using the binomial logistic likelihood loss and with *a priori* elasticnet predictor screening. However, using the AUROCt loss led to larger weights for random survival forest and survival neural network; see Supplementary Table 2.

Predictive performance

Table 2 presents the predictive performance. In DIVAT, the survival SL achieved better discrimination than the KTFS, with a tAUROC of 0.83 (95% CI, 0.79-0.87) compared to 0.76 (CI, 0.70-0.82). Their mean calibration was similar: 0.93 (CI, 0.66-1.26) for the KTFS and 0.92 (CI, 0.78-1.05) for the survival SL. However, for the other calibration measures, the KTFS was better than the survival SL (Figure 3). Regarding the overall performance, the two CPMs were equivalent with a Brier score of 0.10 (CIs, 0.09-0.12 and 0.08-0.11).




Figure 2: Survival curves for each cohort. Notes: The survival probability axis is trimmed before 70% to enhance visibility. The samples are selected among the survivors at one year, i.e., the time of the Kidney Transplant Failure Score computation.

Discrimination was stable over time with a tAUROC of 0.80 (CI, 0.77-0.84) and 0.80 (CI, 0.76-0.83) for the KTFS and the survival SL, respectively. Calibration fluctuated over time for both CPMs, without a clear difference between the two CPMs. Overall performances remained stable over time, with a Brier score of 0.11 (CI, 0.10-0.12) for both KTFS and SL.

Table 1: Characteristics of the patients for the development in DIVAT and the temporal validation approximately ten years later in EKITE.

	DIVAT N = 2,169	EKITE n = 2,326	P-value ^a
Recipient age (years), Mean (SD)	48.0 (13.0)	53.5 (13.5)	<0.001
Donor age (years), Mean (SD)	45.2 (15.8)	55.0 (16.5)	<0.001
Body mass index (kg/m ²), Mean (SD)	23.6 (4.3)	24.9 (4.4)	<0.001
Cold ischemia time (hours), Mean (SD)	23.5 (8.8)	18.3 (6.7)	<0.001
1-year eGFR (mL/min), Mean (SD)	51.2 (18.0)	56.1 (22.9)	<0.001
HLA-incompatibilities, Median [IQR]	3.0 [2.0 - 4.0]	3.0 [2.0 - 4.0]	<0.001
Last donor Cr. (μmol/L), Median [IQR]	86.0 [67.0 - 112.0]	75.0 [57.0 - 102.0]	<0.001
3-month Cr. (μmol/L), Median [IQR]	133.0 [106.0 - 165.0]	134.0 [108.0 - 168.0]	0.052
6-month Cr. (μmol/L), Median [IQR]	130.0 [106.0 - 160.5]	133.0 [106.0 - 167.0]	0.015
1-year Cr. (μmol/L), Median [IQR]	130.0 [106.0 - 160.0]	132.0 [106.0 - 165.0]	0.197
3-month Pr. (g/day), Median [IQR]	0.2 [0.1 - 0.4]	0.0 [0.0 - 0.0]	<0.001
6-month Pr. (g/day), Median [IQR]	0.2 [0.1 - 0.4]	0.0 [0.0 - 0.0]	<0.001
1-year Pr. (g/day), Median [IQR]	0.2 [0.1 - 0.4]	0.0 [0.0 - 0.0]	<0.001
Male recipients, n (%)	1,342 (61.9%)	1,432 (61.5%)	0.814
Male donors, n (%)	1,367 (63.3%)	1,296 (55.7%)	<0.001
Previous transplantation, n (%)			0.250
0	1,754 (80.9%)	1,837 (78.9%)	
1	344 (15.9%)	407 (17.5%)	
2+	71 (3.3%)	85 (3.6%)	
Acute rejection in the first year post-transplantation, n (%)	518 (23.9%)	218 (9.4%)	<0.001
Abbreviations: Cr., creatinine; eGFR, estimated graft filtration rate; HLA, human leukocyte antigen; IQR, interquartile range; Pr., proteinuria; SD, standard deviation.			
^a Continuous variables approximately normally distributed: t-test; Continuous variables not normally distributed: Mann-Whitney test; and categorical variables: Chis-square test.			

Table 2: Performance of the models at the development in DIVAT and the temporal validation approximately ten years later in EKITE.

	KTFS		Survival SL	
	DIVAT N = 2,169	EKITE N = 2,326	DIVAT N = 2,169	EKITE N = 2,326
Discrimination				
AUROCt	0.76 (0.72-0.81)	0.80 (0.77-0.84)	0.83 (0.79-0.87)	0.80 (0.76-0.83)
Calibration				
Mean calibration	0.93 (0.80-1.08)	1.16 (1.02-1.30)	0.92 (0.78-1.05)	1.06 (0.94-1.20)
Weak calibration	0.94 (0.78-1.06)	0.83 (0.73-0.94)	1.32 (1.17-1.45)	1.14 (1.02-1.27)
ICI	0.01 (0.00-0.04)	0.03 (0.02-0.05)	0.04 (0.02-0.05)	0.03 (0.02-0.05)
Overall performance				
Brier score	0.10 (0.09-0.12)	0.11 (0.10-0.12)	0.10 (0.08-0.11)	0.11 (0.10-0.12)

Values presented: Estimated value (95% Confidence interval).

Abbreviations: AUROCt, area under the time-dependent receiver operating curve; ICI, integrated calibration index; KTFS, Kidney Transplant Failure Score.




Figure 3: Flexible calibration curves. Filled areas show the 95% confidence interval.

Similar trends were observed for the alternative survival SL implementations (Supplementary Table 3). Mean calibration, moderate calibration, and Brier scores were similar to Table 2 and remained stable over time. All other implementations showed worse weak calibrations (including elasticnet screening). As expected, the discrimination was the highest in DIVAT using both AUROCt as loss and with elasticnet screening, reaching 0.94 (CI, 0.92-0.96). However, the AUROCt was similar to the Brier Score-based SL in EKITE (0.81; CI, 0.77-0.85).

Discussion

One of the many challenges researchers face when developing a CPM is choosing a statistical method. Tradeoffs between different approaches may include interpretability, ease of implementation, or statistical performance. In this study, we focused on the stability of performance over time. A steadier CPM is less sensitive to population shift and requires less frequent refitting or updating.²⁸ We compared a Cox model to a survival SL that combines statistical models and machine learning algorithms. We showed that performance evolution was similar between the two. However, survival SL achieved better discrimination on the population used to fit it at the cost of inferior weak calibration. The survival SL overestimated the graft survival on the population used to fit it, while the KTFS underestimated the graft survival when applied to a future dataset. The calibration slope showed a tendency to decrease over time, perhaps explaining why the survival SL was no longer overestimating the performance in the temporal validation.

Such CPMs' calibration drift occurs because healthcare is a dynamic environment. New patient profiles can be brought by new facilities, giving easier access to healthcare, and new clinical guidelines. The natural ageing of the population may also shift the population characteristics. Alternatively, changing how a predictor is measured can also yield calibration drift.²⁹ In our motivating case, the donors became older due to the increased use of marginal graft, while the acute rejection prevalence was recently lowered by using higher immunosuppression.^{17,30}

Our results differ from those of Davis et al.'s simulation study,¹⁸ which showed that neural networks and random forests yielded better robustness to calibration drift than regression. They used a much larger sample size ($n=170,675$ during the development period and $n=1,671,276$ during the validation period), potentially favoring data-hungry machine learning algorithms.³¹ The need for larger sample sizes may be further exacerbated by right censoring in our study. Furthermore, methods themselves may deal differently with right censoring, impacting the performance. For instance, Baralou et al. showed through simulations that random survival forests are more sensitive to the censoring level than a Cox proportional hazard model.³² Lastly, Davis et al. studied regression models with main terms only, while KTFS includes non-linear functional forms and clinically relevant interactions.^{4,18} In contrast, our SL prediction was mainly based on a Cox model conditioning on main terms only and with no interactions. Including domain knowledge, such as plausible interactions or relevant predictors, in the SL's candidate learners should likely improve its performance.

Some limitations must be acknowledged. We only investigated one CPM at two time-points, and some of the observed results may be attributable to sampling variability. Benchmarking several CPMs at several times and on several datasets would be ideal. However, many recent

literature reviews conclude that CPMs are generally poorly developed,³³⁻³⁷ challenging the benchmarking of several CPMs. Simulation studies could be another solution to compare machine learning-based and regression-based CPMs, but they are farther from reality and computationally more intensive, while ground truth is not needed to validate prediction.³⁸ In addition, we did not consider mortality as a competing event but as a censoring event. Therefore, the predicted risk is the hypothetical risk in a counterfactual world in which the competing event does not exist,³⁹ changing the decision-making process. However, (i) our study is methodological by design and will not impact clinical decision-making, and (ii) only 3.5% of the individuals used at development died during the follow-up. A recent external validation study of the KTFS showed no difference in performance when accounting for competing risk or not.⁵

Conclusion

Should we favor regression or machine learning methods to build a CPM? The present study shows that the survival SL (a machine learning technique that may also incorporate regressions) achieved better discrimination and worse weak calibration than a Cox model. In the temporal validation conducted ten years later, both methods were subject to calibration drift. Therefore, population shifts over time did not seem to impact one method more than the other. However, poor calibration at development is often detrimental and temporal recalibration of survival SL risks to maintain the suboptimal weak calibration. In the end, the choice will depend on the CPM's intended use. For instance, one may want to optimize discrimination when the goal is scarce resource allocation (e.g., by prioritizing medically urgent recipient candidates with a high risk of dying without transplantation). However, achieving correct calibration is crucial for patient information and shared decision-making according to the estimated risk of events.

Data Statement

The EKITE network restricts access to clinical data, as these are confidential and are subject to the General Data Protection Regulation. See Lorent et al.²³ for information on requesting access to the data from each EKITE center's scientific and ethics committee.

Acknowledgments

We thank the people involved in the EKITE network. This study was approved by the Université de Montréal 's clinical ethics committee (#2023-4811). AC was supported by an IVADO postdoctoral fellowship #2022-7820036733. HC is a Fonds de recherche du Québec senior scholar. RWP holds the Albert Boehringer I Chair. MES holds the Canada Research Chair in Causal Inference and Machine Learning in Health Science.

Author Contributions

AC designed the study. AC and KAF were involved in data collection and curation. EP performed the analyses with input from AC, MES and RWP. All authors interpreted the results. AC wrote the manuscript, which was revised by all coauthors.

References

1. Liyanage T, Ninomiya T, Jha V, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. *The Lancet*. 2015;385(9981):1975-1982. doi:10.1016/S0140-6736(14)61601-9
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. *N Engl J Med*. 1999;341(23):1725-1730. doi:10.1056/NEJM199912023412303
3. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. *Kidney Int*. 1996;50(1):235-242. doi:10.1038/ki.1996.307
4. Foucher Y, Daguin P, Akl A, et al. A clinical scoring system highly predictive of long-term kidney graft survival. *Kidney International*. 2010;78(12):1288-1294. doi:10.1038/ki.2010.232
5. Chatton A, Feugo KA, Pilote E, Cardinal H, Platt RW, Schnitzer ME. A Canada-European external validation of the Kidney Transplant Failure Score. *medRxiv (not peer-reviewed)*. 2024. doi:10.1101/2024.10.31.24316511
6. Wei LJ. The accelerated failure time model: A useful alternative to the cox regression model in survival analysis. *Statistics in Medicine*. 1992;11(14-15):1871-1879. doi:10.1002/sim.4780111409
7. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. *The Annals of Applied Statistics*. 2008;2(3):841-860. doi:10.1214/08-AOAS169
8. Katzman JL, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y. DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. *BMC Medical Research Methodology*. 2018;18(1):24. doi:10.1186/s12874-018-0482-1
9. van der Laan M, Polley EC, Hubbard AE. Super Learner. *Statistical Applications in Genetics and Molecular Biology*. 2007;6(1):Article 25. doi:10.2202/1544-6115.1309
10. Pirracchio R, Petersen ML, Carone M, Rigon MR, Chevret S, van der Laan MJ. Mortality prediction in the ICU: can we do better? Results from the Super ICU Learner Algorithm (SICULA) project, a population-based study. *Lancet Respir Med*. 2015;3(1):42-52. doi:10.1016/S2213-2600(14)70239-5
11. Chatton A, Bally M, Lévesque R, Malenica I, Platt RW, Schnitzer ME. Personalized dynamic super learning: an application in predicting hemodiafiltration convection volumes. *Journal of the Royal Statistical Society Series C: Applied Statistics*. Published online November 29, 2024:qlae070. doi:10.1093/jrssc/qlae070
12. Smith H, Sweeting M, Morris T, Crowther MJ. A scoping methodological review of simulation studies comparing statistical and machine learning approaches to risk prediction for time-to-event data. *Diagnostic and Prognostic Research*. 2022;6(1):10. doi:10.1186/s41512-022-00124-y
13. Liu P, Sawhney S, Heide-Jørgensen U, et al. Predicting the risks of kidney failure and death in adults with moderate to severe chronic kidney disease: multinational, longitudinal, population based, cohort study. *BMJ*. 2024;385:e078063. doi:10.1136/bmj-2023-078063
14. Polley EC, van der Laan MJ. Super Learning for Right-Censored Data. In: van der Laan MJ, Rose S, eds. *Targeted Learning: Causal Inference for Observational and Experimental Data*. Springer Series in Statistics. Springer; 2011:249-258. doi:10.1007/978-1-4419-9782-1_16
15. Golmakani MK, Polley EC. Super Learner for Survival Data Prediction. *Int J Biostat*. 2020;16(2). doi:10.1515/ijb-2019-0065
16. Infante G, Miceli R, Ambrogi F. Sample size and predictive performance of machine learning methods with survival data: A simulation study. *Statistics in Medicine*. 2023;42(30):5657-5675. doi:10.1002/sim.9931
17. Mella A, Calvetti R, Barreca A, Congiu G, Biancone L. Kidney transplants from elderly donors: what we have learned 20 years after the Crystal City consensus criteria

- meeting. *J Nephrol*. Published online March 6, 2024. doi:10.1007/s40620-024-01888-w
18. Davis SE, Lasko TA, Chen G, Siew ED, Matheny ME. Calibration drift in regression and machine learning models for acute kidney injury. *Journal of the American Medical Informatics Association*. 2017;24(6):1052-1061. doi:10.1093/jamia/ocx030
 19. Simon N, Friedman JH, Hastie T, Tibshirani R. Regularization Paths for Cox's Proportional Hazards Model via Coordinate Descent. *Journal of Statistical Software*. 2011;39:1-13. doi:10.18637/jss.v039.i05
 20. Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. *Stat Med*. 2002;21(15):2175-2197. doi:10.1002/sim.1203
 21. Phillips RV, van der Laan MJ, Lee H, Gruber S. Practical considerations for specifying a super learner. *International Journal of Epidemiology*. 2023;52(4):1276-1285. doi:10.1093/ije/dyad023
 22. Foucher Y, Sabathé C. survivalSL: Super Learner for Survival Prediction from Censored Data. Published online 2024. <https://CRAN.R-project.org/package=survivalSL>
 23. Lorent M, Foucher Y, Kerleau K, et al. The EKITE network (epidemiology in kidney transplantation - a European validated database): an initiative epidemiological and translational European collaborative research. *BMC Nephrology*. 2019;20(1):365. doi:10.1186/s12882-019-1522-8
 24. Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. *Stat Med*. 2013;32(30):5381-5397. doi:10.1002/sim.5958
 25. Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A calibration hierarchy for risk models was defined: from utopia to empirical data. *Journal of Clinical Epidemiology*. 2016;74:167-176. doi:10.1016/j.jclinepi.2015.12.005
 26. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. *Biometrics*. 2000;56(3):779-788. doi:10.1111/j.0006-341x.2000.00779.x
 27. McLernon DJ, Giardiello D, Van Calster B, et al. Assessing Performance and Clinical Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox Proportional Hazards Models. *Ann Intern Med*. 2023;176(1):105-114. doi:10.7326/M22-0844
 28. Binuya MAE, Engelhardt EG, Schats W, Schmidt MK, Steyerberg EW. Methodological guidance for the evaluation and updating of clinical prediction models: a systematic review. *BMC Medical Research Methodology*. 2022;22(1):316. doi:10.1186/s12874-022-01801-8
 29. Luijken K, Wynants L, Smeden M van, et al. Changing predictor measurement procedures affected the performance of prediction models in clinical examples. *Journal of Clinical Epidemiology*. 2020;119:7-18. doi:10.1016/j.jclinepi.2019.11.001
 30. Lim MA, Kohli J, Bloom RD. Immunosuppression for kidney transplantation: Where are we now and where are we going? *Transplantation Reviews*. 2017;31(1):10-17. doi:10.1016/j.trre.2016.10.006
 31. van der Ploeg T, Austin PC, Steyerberg EW. Modern modelling techniques are data hungry: a simulation study for predicting dichotomous endpoints. *BMC Medical Research Methodology*. 2014;14(1):137. doi:10.1186/1471-2288-14-137
 32. Baralou V, Kalpourtzi N, Touloumi G. Individual risk prediction: Comparing random forests with Cox proportional-hazards model by a simulation study. *Biometrical Journal*. 2023;65(6):2100380. doi:10.1002/bimj.202100380
 33. Haller MC, Aschauer C, Wallisch C, et al. Prediction models for living organ transplantation are poorly developed, reported, and validated: a systematic review. *Journal of Clinical Epidemiology*. 2022;145:126-135. doi:10.1016/j.jclinepi.2022.01.025
 34. Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. *BMJ*. Published online April 7, 2020:m1328. doi:10.1136/bmj.m1328

35. Damen JAAG, Hooft L, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. *BMJ*. 2016;353:i2416. doi:10.1136/bmj.i2416
36. Verburg IWM, Atashi A, Eslami S, et al. Which Models Can I Use to Predict Adult ICU Length of Stay? A Systematic Review. *Crit Care Med*. 2017;45(2):e222-e231. doi:10.1097/CCM.0000000000002054
37. Kaboré R, Haller MC, Harambat J, Heinze G, Leffondré K. Risk prediction models for graft failure in kidney transplantation: a systematic review. *Nephrology Dialysis Transplantation*. 2017;32(suppl_2):ii68-ii76. doi:10.1093/ndt/gfw405
38. Friedrich S, Friede T. On the role of benchmarking data sets and simulations in method comparison studies. *Biometrical Journal*. 2024;66(1):2200212. doi:10.1002/bimj.202200212
39. van Geloven N, Swanson SA, Ramspek CL, et al. Prediction meets causal inference: the role of treatment in clinical prediction models. *Eur J Epidemiol*. 2020;35(7):619-630. doi:10.1007/s10654-020-00636-1

Supplementary materials of “What if we had built a prediction model with a survival super learner instead of a Cox model 10 years ago?” from Chatton, Pilote, Assob Feugo, Cardinal, Platt & Schnitzer

Supplementary table 1: Reproducibility information.

Purpose	R Package	Version	Authors	Learner or measure	Hyperparameters
Candidate learners	flexsurv [1]	2.2.1	Jackson C.	Gamma-distributed AFT model	-
				Weibull-distributed AFT model	-
				Royston & Parmar model [2]	k = 3
	survival	3.4-0	Therneau T.	Cox model	-
	glmnet [3,4]	4.1-6	Friedman J., Hastie T., Tibshirani R., Narasimhan B., Tay K., Simon N., Qian J. & Yang J.	Elasticnet Cox model	$\alpha = 0.9$ (0.2 [†])
					$\lambda = 0.003$ (0.028 [†])
	randomForestSRC	3.2.0	Ishwaran H. & Kogalur U.B.	Random survival forest [5]	nodesize = 20
					mtry = 3
					ntree = 500
	survivalmodels	0.1.13	Sonabend R.	Survival neural network [6]	n.nodes = 20
					decay = 0.1
					batch.size = 256
					epochs = 1
Python to R conversion	reticulate	1.28	Ushey K., Allaire J. & Tang Y.	-	-
Super Learner	survivalSL	0.94	Foucher Y. & Sabathe C.	-	-
Performance measures	timeROC	0.4	Blanche P.	AUROCt [7]	-
	rms	6.4-1	Harrel Jr F.E.	Calibration	-
	riskRegression	2022.11.28	Gerds T.A. & Kattan W. (8)	Brier Score	-

R version: 4.2.2, Python version: 3.12 (Windows 10 x64), seed set randomly to 9511.
Abbreviations: AFT, Accelerated Failure Time; AUROCt, Area Under the time-dependent Receiver Operating Curve.
[1] Jackson C. (2016). Journal of Statistical Software, 70(8), 1-33. [2] Royston P. and Parmar M. (2002). Statistics in Medicine 21(1):2175-2197. [3] Friedman J., Hastie T. and Tibshirani R. (2010). Journal of Statistical Software, 33(1), 1-22. [4] Simon N., Friedman J., Hastie T. and Tibshirani R. (2011). Journal of Statistical Software, 39(5), 1-13. [5] Ishwaran H., Kogalur U.B., Blackstone E.H. and Lauer M.S. (2008). Ann. Appl. Statist. 2(3), 841–860. [6] Katzman J. L., Shaham U., Cloninger A., Bates J., Jiang T., and Kluger, Y. (2018). BMC Medical Research Methodology, 18(1), 24. [7] Blanche P., Dartigues J.-F. and Jacqmin-Gadda H. (2013). Statistics in Medicine, 32(30), 5381-5397. [8] Gerds T.A. and Kattan M.W. (2021). Medical Risk Prediction Models: With Ties to Machine Learning (1st ed.) Chapman and Hall/CRC.
[†]Value for screening.

Supplementary Table 2: Candidate learners’ weights by survival super learner

implementations.

Candidate learner	All KTFS predictors			Elasticnet screening		
	BS	NBLL	AUROC	BS	NBLL	AUROC
Gamma-distributed AFT model	0	0.02	0	0	0	0
Weibull-distributed AFT model	0	0	0.15	0	0	0.03
Cox model	0.86	0.63	0.14	0.61	0.74	0.17
Elasticnet Cox model [†]	0	0	0.10	-	-	-
Royston-Parmar model	0	0	0.04	0	0	0.02
RSF	0.14	0.35	0.49	0.39	0.26	0.71
SNN	0	0	0.07	0	0	0.06

Abbreviations: AFT, Accelerated Failure Time; AUROC, Area Under The Receiver Operating Curve; BS, Brier Score; NBLL, Negative Binomial log-Likelihood; RSF, Random Survival Forest; and SNN, Survival Neural Network.
[†] Elasticnet was removed from the pool of candidate learners when used for screening.

Supplementary Table 3: Performance of the alternative survival super learners at the development and approximately ten years later.

	All KTFS predictors				Elasticnet screening					
	NBLL		AUROct		Brier Score		NBLL		AUROct	
	DIVAT N = 2,169	EKiTE N = 2,326	DIVAT N = 2,169	EKiTE N = 2,326	DIVAT N = 2,169	EKiTE N = 2,326	DIVAT N = 2,169	EKiTE N = 2,326	DIVAT N = 2,169	EKiTE N = 2,326
Discrimination										
AUROct	0.87 (0.84-0.90)	0.78 (0.74-0.82)	0.93 (0.91-0.95)	0.82 (0.78-0.85)	0.88 (0.85-0.91)	0.81 (0.78-0.85)	0.84 (0.80-0.88)	0.81 (0.78-0.85)	0.94 (0.92-0.96)	0.81 (0.77-0.85)
Calibration										
Mean calibration	0.92 (0.78-1.06)	1.08 (0.95-1.22)	0.97 (0.82-1.10)	1.06 (0.94-1.18)	0.94 (0.80-1.08)	1.16 (1.01-1.32)	0.92 (0.78-1.06)	1.16 (1.00-1.31)	0.95 (0.82-1.09)	1.11 (0.96-1.25)
Weak calibration	1.51 (1.34-1.66)	0.91 (0.76-1.09)	2.09 (1.90-2.28)	1.57 (1.39-1.76)	1.55 (1.36-1.72)	1.24 (1.09-1.41)	1.39 (1.22-1.55)	1.26 (1.09-1.43)	2.13 (1.86-2.35)	1.34 (1.16-1.54)
ICI	0.06 (0.04-0.07)	0.03 (0.02-0.05)	0.09 (0.07-0.11)	0.05 (0.03-0.06)	0.05 (0.03-0.06)	0.03 (0.02-0.05)	0.04 (0.02-0.05)	0.03 (0.02-0.05)	0.08 (0.06-0.10)	0.03 (0.02-0.05)
Overall performance										
Brier score	0.09 (0.08-0.11)	0.11 (0.10-0.12)	0.09 (0.08-0.10)	0.11 (0.10-0.12)	0.09 (0.08-0.11)	0.10 (0.09-0.12)	0.10 (0.08-0.11)	0.10 (0.09-0.12)	0.08 (0.07-0.09)	0.10 (0.09-0.12)

Values presented: Estimated value (95% Confidence interval).

Abbreviations: AUROct, area under the time-dependent Receiver Operating Curve; ICI, integrated calibration index; KTFS, Kidney Transplant Failure Score; NBLL, Negative Binomial log-Likelihood.